| pubmed-article:642793 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:642793 | lifeskim:mentions | umls-concept:C0003232 | lld:lifeskim |
| pubmed-article:642793 | lifeskim:mentions | umls-concept:C0001675 | lld:lifeskim |
| pubmed-article:642793 | lifeskim:mentions | umls-concept:C0008976 | lld:lifeskim |
| pubmed-article:642793 | lifeskim:mentions | umls-concept:C0034656 | lld:lifeskim |
| pubmed-article:642793 | lifeskim:mentions | umls-concept:C0085669 | lld:lifeskim |
| pubmed-article:642793 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:642793 | pubmed:dateCreated | 1978-6-12 | lld:pubmed |
| pubmed-article:642793 | pubmed:abstractText | One hundred and forty-five adults with acute leukemia were randomized to receive remission induction therapy in or out of a protected environment (PE) with prophylactic antibiotics orally (PA) or systemically (SA). Sixty-three patients were randomized in PE and 82 outside a PE. The proportion of patients who survived long enough to receive an adequate trial was higher in the PE (97%) than out (82%) (P = .01). The complete remission (CR) rate was 71% in and 43% out of the PE (P less than .01). Fifty-five patients received PA and 90 received SA. The CR rates were 61% and 45%, respectively. Of the 145 patients, 73 (50%) developed 102 episodes of major infections. Twenty-six of 63 patients in the PE developed major infection compared to 47 of 82 outside a PE (P = .08). The incidence rate of 13% fatal infections in a PE was significantly smaller than the 28% rate outside a PE (P = .04). The number of days with infections at less than 500 neutrophils/mm3 was also significantly lower inside a PE than outside (P less than .01). When comparing patients receiving SA or PA, there was no statistically significant difference in the incidence of infections. Forty-one patients received OAP Chemotherapy and 104 received adriamycin-OAP plus BCG. The CR rate on OAP was 44% compared with 60% on Ad-OAP + BCG. Infection rates were 76% and 40%, respectively (P less than .01). The median survival time was 72 weeks for patients in PE compared with 42 weeks for patients outside a PE (P less than .01). The prophylactic antibiotic regimens were well tolerated by most patients. This prospective randomized study has demonstrated statistically significant advantages for a lowered risk of fatal infection, higher CR rate and longer survival of patients treated in a PE with prophylactic antibiotics compared with patients treated in a conventional hospital room. Also, there was evidence for the superiority of adriamycin-OAP + BCG treatment compared with OAP. | lld:pubmed |
| pubmed-article:642793 | pubmed:language | eng | lld:pubmed |
| pubmed-article:642793 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:642793 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:642793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:642793 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:642793 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:642793 | pubmed:month | May | lld:pubmed |
| pubmed-article:642793 | pubmed:issn | 0025-7974 | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:KeatingM JMJ | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:BodeyG PGP | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:McCredieK BKB | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:SmithT LTL | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:FreireichE... | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:GuttermanJ... | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:GehanE AEA | lld:pubmed |
| pubmed-article:642793 | pubmed:author | pubmed-author:RodriguezVV | lld:pubmed |
| pubmed-article:642793 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:642793 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:642793 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:642793 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:642793 | pubmed:pagination | 253-66 | lld:pubmed |
| pubmed-article:642793 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-H... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-A... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-A... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-L... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-P... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-A... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-A... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-B... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-A... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-M... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-T... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-D... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-R... | lld:pubmed |
| pubmed-article:642793 | pubmed:meshHeading | pubmed-meshheading:642793-E... | lld:pubmed |
| pubmed-article:642793 | pubmed:year | 1978 | lld:pubmed |
| pubmed-article:642793 | pubmed:articleTitle | Randomized trial of protected environment--prophylactic antibiotics in 145 adults with acute leukemia. | lld:pubmed |
| pubmed-article:642793 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:642793 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:642793 | pubmed:publicationType | Comparative Study | lld:pubmed |
| pubmed-article:642793 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
| pubmed-article:642793 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:642793 | lld:pubmed |
